Summary Anastrozole is the first aromatase inhibitor to show a significant survival advantage over megestrol acetate in post-menopausal women with advanced breast cancer. The rationale for extending the use of aromatase inhibitors to the treatment of early breast cancer is based on the efficacy observed in the advanced setting, combined with good tolerability and a convenient dosing regimen. Furthermore, oestrogen deprivation by ovarian ablation (similar to oestrogen antagonism with tamoxifen) is already established as an effective adjuvant treatment in premenopausal women with modality breast cancer. Anastrozole produces a profound suppression of plasma oestrogen levels which is greater than that obtained with earlier aromatase inhibitors (formestane, aminoglutethimide) or megestrol acetate. This could account for the differences in clinical efficacy seen between anastrozole and megestrol acetate. In terms of benefits over other endocrine agents, anastrozole causes significantly less weight gain than megestrol acetate; it does not have the partial agonist activity of tamoxifen, and is unlikely to lead to tumour stimulation in patients resistant to tamoxifen or to exert proliferative effects on the endometrium. The lack of oestrogen agonist activity, however, may possibly have detrimental effects on bone mineral density and blood lipid profile. Current clinical trials are investigating the efficacy and safety of anastrozole in the early breast cancer setting. The results of these trials will help to determine whether anastrozole has any benefits over tamoxifen, the current treatment of choice in post-menopausal women with early breast cancer.
The introduction of the new generation of non-steroidal aromatase inhibitors, as typified by anastrozole, presents an exciting opportunity in the treatment of breast cancer. These agents provide selective (i.e. they do not interact with other enzymes involved in adrenal steroid synthesis) and potent inhibition of the enzyme aromatase (Yates et al, 1996) , with a subsequent profound suppression of plasma oestrogens. These properties are combined with good tolerability and a convenient, once-daily dosing regimen (Buzdar et al, 1996a) . The new aromatase inhibitors may have improved efficacy compared with the standard, second-line endocrine therapies, megestrol acetate and aminoglutethimide. Anastrozole is the first aromatase inhibitor to show a significant survival advantage over megestrol acetate in post-menopausal women with advanced breast cancer who have failed on prior tamoxifen treatment (Roseman et al, 1997) . In an overview analysis of two prospective, randomized, phase III trials (Jonat et al, 1995 (Jonat et al, , 1996 Buzdar et al, 1996a; Budzar et al, 1997) , anastrozole increased the median survival time from 22.5 months (with megestrol acetate) to 26.7 months (P = 0.02) and the 2-year survival rate from 46.3% to 56.1 % at a median follow-up duration of 31 months (Roseman et al, 1997) . The finding that adjuvant therapy (ovariectomy or tamoxifen treatment) may 'cure' early breast cancer but not advanced disease (despite objective tumour responses) suggests that even modest differences in the effects of drugs used in advanced disease could translate into a real survival benefit in the adjuvant setting.
Anastrozole is the first endocrine agent since tamoxifen to enter large-scale clinical trials of adjuvant therapy in post-menopausal women. This paper describes the rationale for the use of aromatase 
RATIONALE FOR ADJUVANT USE OF AROMATASE INHIBITORS
The rationale for extending the use of aromatase inhibitors to the treatment of early breast cancer in post-menopausal women is based on several considerations.
Mechanism of action
Oestrogen deprivation by ovarian ablation is already established as an effective adjuvant treatment in premenopausal women. The beneficial effect of oestrogen antagonism in the treatment of early breast cancer in post-menopausal women has been clearly demonstrated for tamoxifen, which currently may be regarded as the 'gold standard' in this patient population (Early Breast Cancer Trialists' Collaborative Group, 1992) . It is therefore possible that oestrogen deprivation through aromatase inhibition could be advantageous in the early breast cancer setting. Indeed, the new-generation aromatase inhibitors have demonstrated superior efficacy compared to conventional therapy for advanced disease (Roseman et al, 1997) .
The new-generation aromatase inhibitors produce profound suppression of oestrogen concentrations. With anastrozole, consistency has been shown between the inhibition of whole-body aromatase activity and the suppression of plasma oestrogen levels down to the limits of detection of the assays used (Table I) (Geisler et al, 1996a) . The earlier aromatase inhibitors aminoglutethimide (MacNeill et al, 1992) and formestane (Jones et al, 1992) provided high levels of aromatase inhibition (although less than those of anastrozole), but not suppression of plasma oestrogen levels to a similar extent (L0nning, 1996) . (Geisler et al, 1996b (Geisler et al, , 1997 . Furthermore, megestrol acetate, which might also function as an oestrogen suppressor, reduced plasma oestrogen levels to a markedly smaller degree than anastrozole (Lundgren et al, 1996) . It could be speculated, therefore, that the differences in oestrogen suppression between anastrozole and megestrol acetate account for the differences in clinical efficacy of these two endocrine agents.
Tolerability
New-generation aromatase inhibitors, such as anastrozole, have good tolerability profiles (Buzdar et al, 1996a) . This is in marked contrast to the first-generation aromatase inhibitor, aminoglutethimide, which is too toxic for adjuvant use (Coombes et al, 1987) . In addition, the progestin, megestrol acetate, is poorly tolerated in the treatment of early disease (Pannuti et al, 1988) , a finding consistent with its less favourable tolerability compared with newgeneration aromatase inhibitors in the treatment of advanced disease (Buzdar et al, 1996a; Dombemowsky et al, 1998) . One major disadvantage associated with megestrol acetate is weight gain; however, this occurs in significantly fewer patients with advanced breast cancer treated with anastrozole. In one study, 12% of patients treated with megestrol acetate experienced weight gain of over 10% compared with 4% of patients treated with anastrozole, 10 mg (P = 0.002), and only 2% of patients treated with anastrozole, 1 mg (P = 0.0001) (Buzdar et al, 1996a) . Moreover, patients who receive megestrol acetate continue to gain weight over time (Figure 1 ). The improved tolerability of anastrozole compared with megestrol acetate has been confirmed over a longer exposure time of 12 months in post-menopausal women with advanced breast cancer (Buzdar et al, 1996b) . This is important in the adjuvant setting where the need for long-term treatment has been established with tamoxifen, which is significantly more effective when given for 5 years compared with 2 years (Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group, 1996; Fisher et al, 1996; Swedish Breast Cancer Cooperative Group, 1996) .
Adverse events
Based on its mechanism of action, anastrozole would not be expected to exhibit the partial agonist activity associated with anti-oestrogens, such as tamoxifen (Yates et al, 1996) . Although anastrozole's (Figure 2) (Baum et al, 1998) . The main assessments are time to breast cancer recurrence, overall survival and tolerability. It will be interesting to see whether the superiority of the aromatase inhibitor-tamoxifen combination over tamoxifen alone in the rat tumour model translates into the clinical setting (Zaccheo et al, 1993; Tominaga et al, 1990) .
Although clinical trials of a number of aromatase inhibitors are in progress, only the ATAC study assesses the combination of an 14 PE L0nning aromatase inhibitor (anastrozole) plus tamoxifen in one of the CONCLUSIONS treatment arms. Tamoxifen levels were found to be reduced when the agent was administered in combination with the earlier
The new potent aromatase inhibitors, such as anastrozole, have aromatase inhibitor, aminoglutethimide (Lien et al, 1990) . Data are proven benefits in the treatment of advanced breast cancer. It is now available showing that tamoxifen levels are unaffected when hoped that the current trials of adjuvant treatment with anastrozole it is co-administered with anastrozole (Dowsett et al, 1998) . As a will confirm the benefit of extending the use of these agents to the result, the two endocrine therapies can be included in combination treatment of early breast cancer in terms of efficacy, tolerability without compromising the efficacy of tamoxifen.
and patient acceptance. This will help to establish their place in the treatment of early breast cancer in post-menopausal women.
Arimidex-Nolvadex (ARNO) trial
A second anastrozole study, the ARNO trial conducted by the Figure 3 Protocol for the ARNO trial aromatisation in breast cancer patients. Eur J Cancer 28A: 1712-1716 
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